If there's a diet, Janet McCaskill says, she's done it ... and they're likely not going to be able to afford the FDA-approved ...

The U.S. Food and Drug Administration (FDA) has approved flurpiridaz F-18 (Flyrcado; GE Healthcare), a first-of-its-kind positron emission tomography (PET) imaging agent, for use in adult patients ...

Ten years after first collecting an FDA approval, it’s time for version number two. Exact Sciences has received an agency green light for Cologuard Plus, the next generation of its mainstay ...

The U.S. Food and Drug Administration (FDA) recently approved the first two drugs to treat the rare lysosomal storage disorder Niemann-Pick disease type C. Both of these drugs were given the green ...

The Food and Drug Administration (FDA) last week approved Bristol Myers Squibb’s antipsychotic drug Cobenfy (xanomeline and trospium chloride), the first schizophrenia treatment with an entirely new ...

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic obstructive pulmonary disease (COPD) is inadequately controlled with inhaler ...

The U.S. Food and Drug Administration (FDA) has approved flurpiridaz F-18 (Flyrcado; GE Healthcare), a first-of-its-kind positron emission tomography (PET) imaging agent, for use in adult patients ...

The FDA has approved a new injectable form of the multiple sclerosis drug ocrelizumab for use in adults with relapsing and progressive forms of the disease. Multiple sclerosis occurs when the body ...

People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies ...

A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...

The US FDA has approved Bristol ... beginning with today’s approval for schizophrenia.” Bristol Myers Squibb plans to make Cobenfy, a twice-daily pill, available by late October.

The U.S. Food and Drug Administration (FDA) approved a novel antipsychotic schizophrenia drug late Thursday, marking the first new treatment in decades for the mental health condition that affects ...